Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PainReform","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"PainReform","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PainReform Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"PainReform","sponsor":"Lotus Clinical Research","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trialof PRF-110 in Patients Undergoing Bunionectomy Surgery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by PainReform

    Menu

    PainReform

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PainReform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trialof PRF-110 in Patients Undergoing Bunionectomy Surgery

              Details:

              PRF-110 (ropivacaine) is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended postoperative analgesia.

              Lead Product(s): Ropivacaine Hydrochloride

              Therapeutic Area: Neurology Product Name: PRF-110

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lotus Clinical Research

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PainReform

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PainReform Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

              Details:

              PRF-110 is based on the local anesthetic ropivacaine, targeting post-operative pain relief market. PRF-110 is an oil-based, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia.

              Lead Product(s): Ropivacaine Hydrochloride

              Therapeutic Area: Neurology Product Name: PRF-110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PainReform

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Israel
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Israeli Pain Relief Biotech PainReform Files for a $25 million US IPO

              Details:

              The company's lead candidate and first product, PRF-110, is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. Company plans to initiate two Phase 3 trials for PRF-110 soon after the closing of this offering.

              Lead Product(s): Ropivacaine Hydrochloride

              Therapeutic Area: Neurology Product Name: PRF-110

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Maxim Group LLC

              Deal Size: $25.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY